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Symptomatic recurrence of Clostridium difﬁcile infection (CDI) occurs in approximately 20% of patients and
is challenging to treat. Identifying those at high risk could allow targeted initial management and improve
outcomes. Adult toxin enzyme immunoassay–positive CDI cases in a population of approximately 600 000
persons from September 2006 through December 2010 were combined with epidemiological/clinical data.
The cumulative incidence of recurrence ≥14 days after the diagnosis and/or onset of ﬁrst-ever CDI was esti-
mated, treating death without recurrence as a competing risk, and predictors were identiﬁed from cause-
speciﬁc proportional hazards regression models. A total of 1678 adults alive 14 days after their ﬁrst CDI were
included; median age was 77 years, and 1191 (78%) were inpatients. Of these, 363 (22%) experienced a recur-
rence ≥14 days after their ﬁrst CDI, and 594 (35%) died without recurrence through March 2011. Recurrence
risk was independently and signiﬁcantly higher among patients admitted as emergencies, with previous gas-
trointestinal ward admission(s), last discharged 4–12 weeks before ﬁrst diagnosis, and with CDI diagnosed at
admission. Recurrence risk also increased with increasing age, previous total hours admitted, and C-reactive
protein level at ﬁrst CDI (all P < .05). The 4-month recurrence risk increased by approximately 5% (absolute)
for every 1-point increase in a risk score based on these factors. Risk factors, including increasing age, initial
disease severity, and hospital exposure, predict CDI recurrence and identify patients likely to beneﬁt from
enhanced initial CDI treatment.
Symptomatic recurrence of Clostridium difﬁcile infec-
tion (CDI) causes signiﬁcant morbidity and can prove
challenging to treat effectively [1]. It also inevitably in-
creases the risk of C. difﬁcile transmission. Reported
recurrence rates vary from 5% to 50% and typically
are around 20% [2].
In a meta-analysis, recurrence risk factors included
older age, use of C. difﬁcile–provocative antibiotics
after CDI diagnosis, and concomitant receipt of ant-
acids [3]. Other factors identiﬁed in individual studies
include hospital-acquired disease [4]; comorbid con-
ditions, including severe underlying illness [5] or poor
quality of life scores [6]; and previous recurrent CDI [7].
However, most existing studies are relatively small and
hospital based and predate the polymerase chain
reaction (PCR) ribotype 027/sequence type 1 (ST1)/
North American pulsed-ﬁeld gel electrophoresis type 1
(NAP-1) epidemic [3], demonstrating a need for con-
temporaneous large-scale population-based studies.
CDI most commonly recurs within a week [8] after
treatment cessation but can recur up to 6–8 weeks
later [9]. However, because most studies have followed
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patients for only 1–2 months [3], the pattern of longer-term
recurrence is unclear. Up to 50% of apparent relapses have
been identiﬁed as new infections with a different strain [10–
13]; uncertainty about which recurrences represent reinfection
hinders the assessment of risk factors for true relapse [14].
Recent guidelines [15] outline strategies for treating recurrent
CDI. However, if patients at high risk could be identiﬁed earlier,
relapse might be prevented by using novel therapies [1, 16].
Therefore, the objectives of this long-term population-based
study were to identify independent predictors of CDI recur-
rence in Oxfordshire during 2006–2010 and to conﬁrm which
predictors were related to relapses caused by the same strain
by using genotyping.
METHODS
Oxford Radcliffe Hospitals (ORH) NHS Trust provides >90%
of hospital care in Oxfordshire (population, approximately
600 000) and all acute services. The ORH Microbiology Lab-
oratory tests all stool samples from the county, including those
from other healthcare facilities and general practitioners
(primary care). From September 2006, all unformed stools
(taking the shape of the container) positive by enzyme immu-
noassay (EIA) for C. difﬁcile toxins A and B (Meridian Bio-
science, Cincinnati, Ohio) and with sufﬁcient sample
remaining were routinely cultured. Clostridium difﬁcile isolates
were genotyped by multilocus sequence typing (MLST) [17],
typing morphologically distinct colonies separately. Infection
control policy required samples from any admitted patient
with diarrhea (locally deﬁned as ≥3 unformed stools within 24
hours) to be tested for C. difﬁcile and vancomycin treatment to
be initiated empirically, continuing for 14 days if CDI is con-
ﬁrmed. From May 2007, all unformed stool samples from
patients aged ≥65 years were routinely tested for C. difﬁcile ac-
cording to UK Department of Health policy (a mandatory test,
typically not meeting the previous diarrhea deﬁnition).
Clostridium difﬁcile MLST data were anonymously linked to
information for ORH hospital admissions and discharges
from April 1997 and mortality from the Infections in Oxford-
shire Research Database (IORD) [18]. Admissions to other
smaller hospitals in the area (including a specialist orthopedic,
a psychiatric, and several community hospitals) were not in-
cluded, although samples taken at these locations were iden-
tiﬁable. The IORD has Research Ethics Committee and UK
National Information Governance Board approval.
We included the ﬁrst CDI for each adult (aged ≥18 years)
from September 2006 through December 2010 (when >99% of
samples had been typed), if the patient had no previous
CDI recorded since April 1997. Included cases therefore had
≥3 months of potential follow-up to the 1 April 2011 data
cutoff. Neither symptom resolution nor antibiotic use is
routinely recorded electronically and, therefore, was not
available for analysis. Because (1) patients received 14 days of
vancomycin treatment, (2) most symptoms resolve before 14
days in successfully treated patients, and (3) UK Department
of Health guidance was not to retest patients with ongoing
diarrhea (ie, without resolution) for 28 days, the primary
outcome was time from ﬁrst-ever CDI to the ﬁrst new EIA-
positive sample ≥14 days later. Analyses therefore were re-
stricted to patients known to be alive 14 days after the ﬁrst
CDI. The cumulative incidence of recurrence over time was
estimated using competing risks methods to account for death
before recurrence. Flexible parametric models were used to
estimate precisely how the unadjusted daily recurrence risk
varied with time from ﬁrst CDI [19]. Cause-speciﬁc pro-
portional hazards (Cox) models were used to estimate effects
of factors theoretically available at treatment initiation (demo-
graphic characteristics, sample characteristics, previous ORH
hospital exposure, and previous healthcare-associated infec-
tions; details in Table 1) on recurrence risk. Independent pre-
dictors were identiﬁed using backward selection with the
Akaike information criterion [20], including pairwise inter-
actions and allowing nonlinear effects of continuous factors
through fractional polynomials. Categorical effects are pre-
sented for factors with signiﬁcant evidence of nonlinearity.
Results from regression models for the cumulative incidence
subhazard for recurrence [21] (rather than the cause-speciﬁc
hazard) were similar (data not shown). In all analyses, patients
not known to have died were censored at their last hospital or
laboratory contact.
Baseline biomarker values were deﬁned as the closest
measurement within (−3, +1) days of the stool sample. Four-
teen biomarkers available for >50% of CDI cases were con-
sidered (white blood cell count, neutrophil count, lymphocyte
count, C-reactive protein level, hemoglobin level, platelet count,
and sodium, potassium, creatinine, urea, albumin, alanine ami-
notransferase, alkaline phosphatase, and bilirubin levels). To
avoid bias and/or loss of power from restricting to complete
cases with all biomarkers measured, associations between bio-
markers and recurrence were estimated, imputing missing
values in the subset of patients with at least 1 observed baseline
biomarker. As recommended, chained estimating equations
[22, 23] were used to create 20 imputations on BoxCox trans-
formed variables [24], including all cofactors listed in Table 1,
allowing nonlinearity in all continuous factors with natural
cubic splines (knots at 10th, 50th, and 90th percentiles [25])
and including log(recurrence time) and the censoring indicator.
Standard errors were estimated across imputations using
Rubin’s rules.
Stata software, version 11.2 (StataCorp, College Station,
Texas), was used for all analyses, which were conducted by
one of the authors (A. S. W.).
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Table 1. Characteristics of First Clostridium difﬁcile Infection, September 2006–December 2010
Levels (for Continuous Factors, Unit
Increase Corresponding to the RR in
the Regression Model)
No. (%) or Median (IQR)
Unadjusted Univariable
Cause-Specific Hazard Model
Factor Overall With Recurrence RR 95% CI
Global P
Value
CDI, No. (%) 1678 (100) 393 (22)
Demographics
Sex, No. (%) Male 711 (42) 146 (21) 1.00 .36
Female 967 (58) 217 (22) 1.10 .90–1.36
Age (y) (/10-y older) 77 (64–85) 79 (71–86) 1.23 1.14–1.32 <.0001
Previous hospital exposure
Ever previously admitted
to ORH, No. (%)a
No 230 (14) 34 (15) 1.00 .11
Yes, <8-h admissions only 108 (6) 22 (20) 1.13 .74–1.75
Yes, ≥1 admission for >8 h 1340 (80) 307 (23) 1.45 1.02–2.07
Last ORH admission,
No. (%)
>1 y ago/never 568 (34) 103 (18) 1.00 .01
Within the last y 1110 (66) 260 (23) 1.33 1.06–1.67
Previous dialysis/
chemotherapy at
ORH, No. (%)
No 1486 (89) 323 (22) 1.00 .97
Yes 192 (11) 40 (21) 1.01 .73–1.40
Previously admitted to
ORH GI ward, No. (%)
No 1090 (65) 241 (22) 1.00 .33
Yes 588 (35) 122 (21) 0.90 .72–1.12
No. of previous
admissions >8 h
(/5 additional >8-h admissions) 2 (1–5) 3 (1–5) 1.18b 1.03–1.36 .02
Total previous h in
hospital (ORH) in
admissions >8 h (h)
(/doubling of total previous h in
hospital)
366 (44–909) 528 (122–1180) 1.16b 1.09–1.24 <.0001
Days since last
discharged
(/additional 6 mo since last ORH
discharge)
96 (23–870) 77 (22–472) 0.96 .90–1.01 .14
Discharged in last 7 d,
No. (%)
No 1567 (93) 331 (21) 1.00 .07
Yes 111 (7) 32 (29) 1.41 .98–2.02
Likely source of first
infection (IDSA/SHEA),
No. (%) [15]
Hospital onset, healthcare-associated 880 (52) 185 (21) 1.00 <.001
Community onset, healthcare-
associated
334 (20) 80 (24) 1.07 .82–1.39
Indeterminate 127 (8) 45 (35) 1.77 1.27–2.45
Community-associated 337 (20) 53 (16) 0.64 .47–.86
Previous MRSA, No. (%) No 1503 (90) 312 (21) 1.00 .01
Yes 175 (10) 51 (29) 1.45c 1.08–1.95
Sample characteristics
Season, No. (%) Winter (Dec/Jan/Feb) 424 (25) 81 (19) 1.00 .35
Spring (Mar/Apr/May) 388 (23) 86 (22) 1.18 .87–1.60
Summer ( Jun/Jul/Aug) 431 (26) 98 (23) 1.31 .97–1.76
Autumn (Sep/Oct/Nov) 435 (26) 98 (23) 1.20 .89–1.61
Calendar year (/additional y) 2008 (2007–2009) 2008 (2007–2009) 0.93 .85–1.02 .11
Mandatory EIA test
(mild diarrhea), No. (%)
No (requested by clinician) 1404 (84) 316 (23) 1.00 .01
Yes (not requested) 274 (16) 47 (17) 0.68 .50–.92
Previous negative
EIA test
Ever 714 (43) 187 (26) 1.49 1.21–1.83
Never 964 (57) 176 (18) 1.00 <.0001
Previous negative
EIA test
In last 14 d 452 (27) 261 (21) 1.11 .88–1.40
Not in last 14 d 1226 (73) 102 (23) 1.00 .37
Location where first
sample taken
Inpatient (overnight) 1191 (71) 260 (21) 1.00 .58
Primary care 294 (18) 63 (22) 0.83 .63–1.09
Outpatient/ED/day case 87 (5) 20 (23) 0.91 .58–1.44
Other hospital 106 (6) 20 (19) 0.88 .56–1.39
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RESULTS
From September 2006 through December 2010, a total of 2043
adults had their ﬁrst CDI (toxin EIA-positive stool sample
with no previous positive). A total of 271 (13%) patients died
within 0–13 days after the EIA-positive sample, and 94 (5%)
had no follow-up after 13 days, leaving 1678 (82%) alive 14
days after the ﬁrst CDI for analysis of recurrence.
Recurrence Rates
Overall, 363 of 1678 (22%) patients experienced a recurrence
(new EIA-positive sample) ≥14 days after their ﬁrst CDI, and
594 (35%) died without recurrence through March 2011.
Median follow-up in those without recurrence was 11 months
(interquartile range [IQR], 2–28 months). Cumulative inci-
dences of recurrence increased to 7% and 16% by 1 and 2
months later, respectively (Figure 1A), corresponding to rates
of 7.4 cases per 100 person-months at risk and 11.3 cases per
100 person-months at risk, respectively. Thereafter, the inci-
dence increased more slowly to 18% and 20% by 3 and 4
months and to 22% and 23% at 1 and 2 years, respectively.
The risk for recurrence was greatest 24 days after the ﬁrst
CDI, 10 days after cessation of treatment (Figure 1B). Of the
363 recurrences, 94 patients (26%) experienced a third CDI
episode (≥14 days after the recurrence), of whom 24 had
further episodes (maximum, 6) through March 2011.
Table 1 continued.
Levels (for Continuous Factors, Unit
Increase Corresponding to the RR in
the Regression Model)
No. (%) or Median (IQR)
Unadjusted Univariable
Cause-Specific Hazard Model
Factor Overall With Recurrence RR 95% CI
Global P
Value
If inpatient at first CDI,
admission specialty
Surgical 376 (32) 65 (17) 1.00 .03
Medical 815 (68) 195 (24) 1.37 1.11–1.68
If inpatient at first CDI,
method of admission
Elective 237 (20) 34 (14) 1.00 <.0001
Emergency 954 (80) 226 (24) 1.58 1.10–2.27
If inpatient at first CDI,
d since admitted
Within 2 d of admission 311 (26) 75 (24) 1.00 .50
>2 d after admission 880 (74) 185 (21) 1.10 .84–1.43
If inpatient at first CDI,
d since admitted
Nonlinear effectd 8 (2–20) 10 (2–22)
On d of admission 128 (11) 35 (27) 1.51d .99–2.30
1–5 d after admission 351 (29) 67 (19) 1.03d .72–1.47
6–14 d after admission 311 (26) 56 (18) 1.00 .03
≥15 d after admission 401 (34) 102 (25) 1.46d 1.06–2.03
Biomarkerse
C-reactive protein (mg/L) (/120 mg/L)f 84 (33–156) 97 (44–>160) 1.69 1.31–2.18 <.0001
White blood cell count
(×109/L)
(/10 × 109/L)f 11.2 (7.8–16.1) 12.2 (7.9–18.3) 1.34 1.15–1.36 <.0001
Neutrophils (×109/L) (/10 × 109/L)f 8.9 (5.6–13.4) 9.7 (5.7–15.4) 1.42 1.20–1.69 <.0001
Lymphocytes (×109/L) (/10 × 109/L)f 11.0 (7.0–16.0) 10.0 (7.0–15.0) 0.84 .73–.97 .02
Albumin (g/L) (/10 g/L) 34 (30–38) 34 (30–37) 0.82 .68–1.00 .05
Urea (mmol/L) (/5 mmol/L)f 6.7 (4.5–11.0) 7.3 (5.1–12.1) 1.09 1.01–1.17 .02
Abbreviations: CDI, Clostridium difficile infection; CI, confidence interval; ED, emergency department; EIA, enzyme immunoassay; GI, gastrointestinal; IDSA,
Infectious Diseases Society of America; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus; ORH, Oxford Radcliffe Hospitals; RR,
relative risk; SHEA, Society for Healthcare Epidemiology of America.
a Excluding current admission if inpatient.
b Univariable model also adjusts for ever vs never previously admitted for >8 h.
c Approximate IQR.
d Significant nonlinearity (P < .0001; univariable model also adjusts for current inpatient), with greatest risk for death on day of admission, then decreasing sharply
and then gradually increasing. Results presented for diagnoses made on day of admission, then approximate tertiles of days from admission to first diagnosis in
inpatients.
e Imputed in the subset of 1295 (77%) patients with at least 1 of the 14 potential biomarkers available (see Methods for details). Reference ranges: C-reactive
protein, 0–8 mg/L; white blood cell count, 4 – 11 × 109/L (no reference range for neutrophils or lymphocytes, which are measured as a percentage of white blood
cell count); albumin, 35 – 50 g/L; urea, 2.5 – 6.7 mmol/L. None of the biomarkers not shown had an effect in univariable models (P > .1).
f Significant interaction between previous MRSA and emergency/elective admission (Table 2), such that previous MRSA increases CDI recurrence risk for
emergency admissions, but decreases CDI recurrence risk for elective admissions (such patients received vancomycin and gentamicin perioperatively in place of
broad-spectrum penicillin-based prophylaxis).
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Risk Factors for Recurrence
As expected, the population was predominantly older (median
age, 77 years), although 302 (18%) were <60 years of age at
ﬁrst CDI (Table 1). A total of 1191 (71%) were inpatients (ad-
mitted a median of 8 [IQR, 2–20] days), and most (1448;
86%) had previously been admitted to ORH facilities (66% in
the past year). In a multivariable model (Table 2), recurrence
risk independently was signiﬁcantly higher among patients ad-
mitted as emergencies, those with previous gastroenterology
ward admission(s), and after diagnosis on day of admission or
≥15 days after admission and also increased with age and
increasing previous total hours in the hospital (all P < .05).
Risks also were higher among those for whom the last inpa-
tient stay was 4–12 weeks before diagnosis (P = .006). Recur-
rence risk was independently lower among those with CDI
diagnosed using a test that had not been clinically requested
(a mandatory test, often for mild diarrhea; P = .07). Patients
without previous hospital admissions generally had fewer
other risk factors, but after adjusting for these, they had
higher recurrence risks. One potential explanation, not assess-
able in our data, would be if such patients were more likely to
be tertiary referrals with other non-ORH hospital exposure.
Other factors (in particular, medical specialty, previous EIA-
negative test result, number of previous admissions, and
discharged in the previous 7 days) were signiﬁcant in only
univariable and not multivariable models (ie, were con-
founded with other factors).
In this multivariable model, 5 major effect modiﬁcations
(interactions) were identiﬁed (Table 2): (1) increased risk at
older ages was augmented in those with previous dialysis/che-
motherapy, (2) increased risks associated with emergency ad-
missions were augmented in those with previous methicillin-
resistant Staphylococcus aureus (MRSA) infection or dialysis/
chemotherapy, (3) recurrence risk increased less strongly with
increasing previous total hours in the hospital in those ad-
mitted as emergencies and/or with previous gastroenterology
ward admissions, (4) risk was signiﬁcantly lower in those with
previous MRSA infection and CDI in an elective admission
(mostly surgical specialties; such patients received vancomycin
and gentamicin perioperatively in place of broad-spectrum
penicillin-based prophylaxis), and (5) recurrence risks varied
less over days from admission to the ﬁrst CDI diagnosis in
medical than in nonmedical inpatients. No other factor listed
in Table 1 had an additional effect in this multivariable model
(P > .2). There also was no evidence of a trend over calendar
year (P = .37) or season (P = .24).
The multivariable model in Table 2 included factors theo-
retically available to clinicians at treatment initiation. Of
importance, after adjusting for these, higher EIA optical
density of the ﬁrst C. difﬁcile test was associated with a higher
risk for recurrence, comparing across absolute values (relative
risk [RR], 1.20 per unit higher [95% conﬁdence interval {CI},
1.06–1.35]; P = .003; median, 1.6 [IQR, 0.5–>2.5]) or compar-
ing the 37% with optical density exceeding the assay maximum
(2.5) with other cases (RR, 1.33; 95% CI, 1.08–1.65; P = .008).
Biomarkers
One or more of the 14 potential biomarkers was available in
1295 patients (77%), imputing missing data in this subgroup.
Only higher C-reactive protein level and higher neutrophil
count at ﬁrst CDI independently increased recurrence risk,
but the effect was much larger for C-reactive protein level
(RR, 1.45 per 120 mg/L [the IQR] higher [95% CI, 1.09–1.93];
P = .01) than for neutrophil count (RR, 1.19 per 10 × 109/L
higher [95% CI, .97–1.45]; P = .09). Effects of other factors
listed in Table 2 were similar after adjusting for these baseline
biomarkers.
Figure 1. Time to recurrence. A, Months to new enzyme immunoassay
(EIA)–positive sample or death ≥14 days after ﬁrst-ever EIA-positive
sample. B, Daily risk of post–14-day new EIA-positive sample. Abbrevi-
ations: AIC, Akaike information criterion; EIA, enzyme immunoassay.
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Table 2. Predictors of Recurrence ≥14 Days After First Clostridium difﬁcile Infection
All Recurrences Multivariable
Cause-Specific Hazard Modela
Shared STs Multivariable Cause-Specific
Hazard Modela
Factor
Levels (Effect in Regression
Model) RR 95% CI
Global
P Value RR 95% CI
Global P
Value
No. of CDI recurrences 363 169
Age (y) (/10-y older) 1.16
1.57
(if previous dialysis/
chemotherapy [interaction
P = .02])
1.07 – 1.26
1.23 – 2.00
.0004
.0003
1.29
1.71
(if previous dialysis/
chemotherapy)
1.13 – 1.48
1.19 – 2.47
.0001
.004
Total previous h in hospital
(ORH) in admissions >8 h (h)
(/doubling of total previous h
in hospital)
1.29
1.12 (if emergency admission
[interaction P= .002])
1.15 (if previous GI admission
[interaction P= .007])
1.17 – 1.42
1.03 – 1.22
1.04 – 1.28
<.0001
.008
.008
1.38
1.15 (if emergency
admission)
1.24 (if previous GI
admission)
1.19 – 1.60
1.01 – 1.30
1.05 – 1.46
<.0001
.03
.009
Ever previously admitted to
ORH
No or <8-h admissions (vs
yes for >8-h admission)
1.99 1.20 – 3.31 .008 2.57 1.18 – 5.62 .02
Mandatory EIA test (mild
diarrhea)
Yes (vs no) 0.74 .53 – 1.03 .07 0.67 .41 – 1.09 .11
If inpatient at first CDI,
admission method
Elective emergency 1.00
2.79
5.10 (if previous MRSA [interaction
P= .0003])
4.74 (if previous dialysis/
chemotherapy [interaction
P = .04])
1.29 – 6.04
2.12 – 12.2
1.96 – 11.4
.006
.0003
.0005
1.00
4.85
9.52
8.79 (if previous dialysis/
chemotherapy)
1.42 – 16.6
2.42 – 37.5
2.23 – 34.6
.01
.001
.002
Previous MRSA Yes (vs no) 0.45 (if not emergency) .23 – .88 .02 0.70 (if not emergency) .31 – 1.59 .39
Previous dialysis/chemotherapy
at ORH
Yes (vs no) 0.77a (if not emergency) .39 – 1.52 .45 1.15a (if not emergency) .46 – 2.82 .77
Previously admitted to ORH GI
ward
Yes (vs no) 2.33 1.13 – 4.78 .02 2.10 .71 – 6.23 .18
If inpatient at first CDI, d since
admitted
On d of admission 1.73b .52 – 5.73 1.15 .21 – 6.31
1 – 5 d after admission 0.50b .21 – 1.19 0.54 .18 – 1.65
6 – 14 d after admission 1.00 .006 1.00 .38
≥15 d after admission 1.84b 1.05 – 3.23 1.37 .62 – 3.04
If inpatient at first CDI,
admission specialty
Medical (vs surgical) 0.98b .34 – 2.79 .97 0.90 .80 – 1.01 .08
Location where first CDI sample
taken
Not inpatient (vs inpatient
overnight)
0.58c .20 – 1.73 .33 0.50 .11 – 2.39 .39
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Strain-Speciﬁc Recurrence Risks
MLST was obtained for 1076 of 1678 (64%) ﬁrst CDI cases:
418 (25%) samples did not yield C. difﬁcile on culture (EIA-
positive culture-negative samples), and 184 (11%) were not
available for culture (28% pre– vs 4% post–September 2007
when staff cover increased). A total of 685 (64%) typed isolates
belonged to phylogenetic clade 1, from 56 STs, including those
corresponding to PCR ribotypes 001, 002, 005, 014, 015, 020,
072, and 106 [26]. A total of 300 typed isolates (28%) belonged
to clade 2 (295 of 300 PCR ribotype 027/ST1), and the remain-
ing 91 (8%) belonged to clades 3, 4, and 5 (Supplementary
Table 1). The crude percentages with recurrence were slightly
higher after initial clade 2 CDI (90 of 300; 30%), compared
with clade 1 (174 of 685; 25%; χ2 P = .13). After adjusting for
risk factors listed in Table 2, recurrence risk appeared to be
slightly higher after clade 2, compared with 1 CDI (RR, 1.17;
95% CI, .90–1.51; P = .24), but was compatible with chance.
Recurrence risk was signiﬁcantly lower for EIA-positive
culture-negative samples (RR [vs clade 1], 0.41 [95% CI,
.29–.58]; P < .0001), supporting previous observations that this
latter group likely represents false EIA-positive results [27, 28].
Relapse Versus Reinfection
Of the 363 recurrences after the ﬁrst CDI, 219 (60%) had STs
determined from both episodes. Making comparisons on the
basis of individual STs, not clade, 169 (77%) recurrences had
the same ST as the initial episode and 50 (23%) had no STs in
common (ie, were new infections). The risk for same-ST re-
currence was highest 14 days after ﬁrst EIA-positive sample
(Figure 2), then declined slowly during the next 2–6 months.
In contrast, the risk for new ST infections peaked 30 days after
the ﬁrst CDI and then decreased sharply; recurrence risk
among the 41 patients (11%) with EIA-positive culture-
negative ﬁrst CDI followed a similar pattern. For the other 103
recurrences (28%; STs not determined for ≥1 isolate), risk was
a mixture distribution (data not shown).
Predictors of the 169 recurrences with shared STs were very
similar to predictors of all 363 recurrences (Table 2); with
relatively small numbers, power was too low to conduct sepa-
rate model selection. As expected, several factors appeared to
have weaker effects on the 50 recurrences with no shared STs
(presumed reinfections; data not shown).
Risk Score for Recurrence Following First CDI
Because predictors of all CDI recurrences were similar to
those for shared ST recurrences, we constructed an integer
risk score (Table 3) based on the multivariable model for all
recurrences (Table 2). The maximum possible score is 15 and
minimum is −2; values of 0–13 were observed in our data set,
with a median of 5 (IQR, 3–6). Models including the single
risk score as a predictor provided an overall ﬁt similar to theLi
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full Table 2 model. Four-month recurrence risk was 6%–48%
across the score (Figure 3); the absolute risk of recurrence 4
months after the ﬁrst CDI increased by approximately 5% for
every 1-point increase in score.
DISCUSSION
In our cohort of nearly 1700 patients surviving 2 weeks after
their ﬁrst CDI, 22% developed a symptomatic CDI recurrence
during the 4-year study period. This is similar to commonly
cited recurrence rates of approximately 20% [2] despite our con-
siderably longer follow-up and robust design accounting for
mortality. Most recurrences occurred within 2 months, but 4%
of patients had recurrences at 2–4 months. The decrease in re-
currence over time may reﬂect the eventual success of multiple
treatment cycles [1, 9] or recovery from underlying illness with
consequent lower exposure to antibiotics and restoration of
more normal bowel ﬂora able to suppress C. difﬁcile growth in
the colon [29]. Structural changes in bowel ﬂora with age may
impair such recovery [30]. Alternatively, because recurrence
is associated with inadequate immune responses [31, 32], re-
peated relapse eventually may generate effective immunity, for
example, to all phase variants of the cell surface–expressed pro-
teins [33].
Two possible explanations exist for symptomatic recurrence:
relapse of the same infection and reinfection. These can be distin-
guished, at least partially, by using strain typing data. In our
study, 23% of recurrences were reinfection with a different strain,
similar to the 26% reported in [14], but lower than the approxi-
mately 50% found by others [10–13]. Relapse may be more
common in our cohort because of older age, compared with
some other studies [11, 13]. Implementation of rigorous infection
control measures [34] may also have reduced the incidence of re-
infection. Of interest, reinfection with a different ST occurred
most frequently 1 month after the ﬁrst CDI (2–3 weeks after treat-
ment cessation), possibly representing reexposure to C. difﬁcile
after clearance of the initial infection, whereas risks for new CDI
with the same ST were greatest 14 days after the ﬁrst CDI. Similar
trends have been seen in other smaller studies [10, 11]. The rela-
tively high prevalence of ST1/027/NAP-1, in 18% of cases, illus-
trates the difﬁculty distinguishing reinfection and relapse using
genotyping schemes, such as MLST or ribotyping, with limited
discriminatory power; the number of reinfections thus may be
underestimated [15]. In the future, whole-genome sequencing
may distinguish same-ST relapses from reinfections with different
variants of common STs. Such distinctions are complicated
further by the possibility of mixed initial or subsequent CDI; this
was rarely identiﬁed in our cohort [35].
Our proposed score (Table 3) provides a summary of impor-
tant risk factors for recurrence that would be present in elec-
tronic patient record systems. Several markers of underlying
health status were either risk factors themselves or augmented
the effect of other risk factors in our large unselected contem-
poraneous population, including increasing age, emergency ad-
mission, previous MRSA infection or colonization, and previous
dialysis or chemotherapy. An initial CDI severe enough to be the
probable cause of admission, to merit testing on the basis of
clinical suspicion, or to increase levels of inﬂammatory markers,
in particular, C-reactive protein, increased recurrence risk. We
also found smaller risk increases with higher EIA optical density
of the ﬁrst CDI, which may reﬂect initial bacterial burden and/or
toxin production [36]. Increasing past hospital exposure or gas-
trointestinal ward admission before the ﬁrst CDI was also associ-
ated with recurrence. The increased recurrence risk after
gastrointestinal admission requires conﬁrmation in additional
studies but may reﬂect increased CDI risk associated with
inﬂammatory bowel disease [37, 38], nasogastric tube placement,
possibly gastrointestinal endoscopy [39], and gastrointestinal
Figure 2. Time to recurrence ≥14 days after ﬁrst Clostridium difﬁcile
infection according to shared or not shared sequence types. A, Months
to new enzyme immunoassay (EIA)–positive sample ≥14 days after ﬁrst-
ever EIA-positive sample. B, Daily risk of new post–14-day EIA-positive
sample. Abbreviations: CID, Clostridium difﬁcile infection; EIA, enzyme
immunoassay; ST, sequence type.
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surgery [40]. The apparent protective effect against CDI recur-
rence of previous MRSA infection or colonization on elective ad-
missions is likely to reﬂect differences in the perioperative (and
other) antibiotics received by this group, in particular, the
replacement of broad-spectrum β-lactam antibiotics with glyco-
peptides and aminoglycosides. Conversely, previous MRSA was
associated with higher recurrence risk in emergency admissions,
possibly reﬂecting greater comorbidity in this group of patients
who were also likely to receive broad-spectrum β-lactams in
addition to glycopeptides. Initial CDI occurring 4–12 weeks after
hospital discharge was also independently associated with recur-
rence. The delay in onset of the initial CDI in such cases may
reﬂect prolonged susceptibility to the effects of hospital exposure
(eg, mediated through failure of the immune system or change in
bowel ﬂora that also subsequently increases recurrence risk). Pre-
viously proposed scores for recurrence risk have been developed
on much smaller hospital populations and have incorporated
clinician opinion [5]. Nevertheless, further work to validate the
score proposed here is essential. Of note, our risk score was con-
structed to capitalize on the types of data available in electronic
patient records; we envisage that it could, for example, be incor-
porated into routine reports of positive CDI test results (if vali-
dated). This goal contrasts with other approaches to risk scoring
for recurrence [5] and severity [41], which have been designed
for use by clinicians at the bedside and often include
Table 3. Score to Predict Clostridium difﬁcile Infection (CDI) Recurrence Following First-Ever CDI Diagnosis
Factor Scoring Criteria Max Min
Patient & health status Age (y) 60–69 70–79 ≥80
Score 1 2 3 3 0
Emergency admission Any emergency admission 1
AND previous MRSA+ 1
AND/OR previous
dialysis/chemotherapy
1 3 0
Severity of initial disease Stool frequency ≥3 unformed stools/da 1
Admission with CDI Sample taken on
day of inpatient admission
1
C-reactive proteinb (mg/L) <35 85–<160 ≥160
Score −1 1 2 4 −1
Past health care
exposure
Type of past admission Past gastroenterology
admission
No past gastroenterology
admission
Total inpatient duration
before admission
Any past admission >2–13 wk >13 wk
Score 1 2 3 3 0
Antibiotic selection (Elective admission
OR community sample)
AND previous MRSA isolatedc
−1 0 −1
Susceptibility to diarrhea
several wk after
hospital exposure
Primary CDI 4–12 wk
after hospital
discharged
Community sample or sample
taken within ≤2 d of inpatient
admission AND patient discharged
from hospital 4–12 wk previously
2 2 0
Total 15 −2
Abbreviations: CDI, Clostridium difficile infection; Max, maximum; Min, minimum; MRSA, methicillin-resistant Staphylococcus aureus; MRSA+, MRSA positive.
a
“Mandatory” tests in our study taken to represent mild diarrhea with <3 unformed stools per day.
b Score 0 if C-reactive protein not measured or not available at first CDI.
c Proxy for receiving vancomycin ± gentamicin rather than co-amoxiclav or other provocative antibiotics for surgical prophylaxis or other treatment.
d Infectious Diseases Society of America/Society for Healthcare Epidemiology of America indeterminate [15].
Figure 3. Time to recurrence ≥14 days after ﬁrst Clostridium difﬁcile
infection according to risk score. Abbreviation: EIA, enzyme immunoassay.
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assessments, such as temperature and endoscopy results not
available in our study.
We did not ﬁnd statistical evidence to support higher recur-
rence risk in clade 2 strains (almost exclusively ST1/027/NAP1),
although we had low power (<40%) to detect a signiﬁcant differ-
ence in recurrence rates of 25% and 30% (as observed). More
than 3 times as many cases would be needed to detect such a
difference with 80% power, although it might still be clinically
important, because every symptomatic recurrence reﬂects an
additional opportunity for C. difﬁcile transmission. However, it
also is clear that CDI virulence remains poorly understood, with
the variable virulence of PCR ribotype 027 strains demonstrated
in vivo [42] and in vitro [43, 44], suggesting that factors at levels
other than strain type may play a role.
Study limitations include the lack of prescribing data,
meaning that we could not directly assess the potentially impor-
tant roles of antibiotics and proton pump inhibitors [3, 45]. The
limited sensitivity/speciﬁcity of EIA testing [28] also has impli-
cations for assessing recurrence; the reduced recurrence rate
after EIA-positive culture-negative initial test results (Figure 2)
supports that these do not represent true CDI. Several factors
included in our risk score may not translate to other healthcare
systems and practices, particularly diarrhea severity. Investi-
gating whether they are speciﬁc to our hospitals or reﬂect
important underlying risk determinants is essential. Finally, the
underlying electronic data sources do not capture resolution or
onset of symptoms, and therefore, our assessment of recurrence
is based on time since the initial diagnosis and samples that
were actually submitted. A proportion of our recurrences there-
fore may be persistent diarrhea. However, we are unlikely to
have missed new symptomatic episodes because fecal sampling
was common (500–1400 EIAs/month; median, 960) with a low
clinical threshold to investigate patients with diarrhea; only 7%
of samples were EIA positive. This limitation also means that
we are unable to distinguish between effects of previously
resolved and ongoing episodes of MRSA infection/colonization
or dialysis/chemotherapy in risk models.
In summary, recurrence after CDI is an important problem.
Early recurrence frequently represents relapse of the same in-
fection. Risk factors, including increasing age, severity of
initial disease, and hospital exposure, can predict recurrence,
in particular, relapse of the same infection, and may identify
patients who would beneﬁt from enhanced treatment of an
initial CDI episode. Late recurrences highlight the ongoing
need for interventions to prevent C. difﬁcile transmission.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://www.oxfordjournals.org/our/_journals/cid/). Supplementary ma-
terials consist of data provided by the author that are published to beneﬁt
the reader. The posted materials are not copyedited. The contents of all
supplementary data are the sole responsibility of the authors. Questions or
messages regarding errors should be addressed to the author.
Notes
Acknowledgments. We thank all the people of Oxfordshire who con-
tribute to the Infections in Oxfordshire Research Database. Research Data-
base Team: P. Bejon, T. Berendt, C. Bunch, D. W. Crook, J. Finney,
J. Gearing (community), H. Jones, L. O’Connor, T. E. A. Peto (principal
investigator), J. Robinson (community), B. Shine, A. S. Walker, D. Waller,
and D. Wyllie.
Financial support. This work was supported by the Oxford National
Institute for Health and Research, NIHR Biomedical Research Centre,
United Kingdom.
Supplement sponsorship. This article was published as part of a supple-
ment entitled “Fidaxomicin and the Evolving Approach to the Treatment of
Clostridium difﬁcile Infection,” sponsored by Optimer Pharmaceuticals, Inc.
Potential conﬂicts of interest. The institution of D. W. C. and
T. E. A. P. received per-case funding from Optimer Pharmaceuticals to
support ﬁdaxomicin trial patient expenses. D. W. C. and T. E. A. P. also
received honoraria from Optimer Pharmaceuticals for participation in
additional meetings related to investigative planning for ﬁdax-
omicin. M. H. W. has received honoraria for consultancy work, ﬁnancial
support to attend meetings, and research funding from bioMérieux,
Optimer, Novacta, Pﬁzer, Summit, The Medicines Company, and Viro-
pharma. All other authors report no potential conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
References
1. Johnson S. Recurrent Clostridium difﬁcile infection: a review of risk
factors, treatments, and outcomes. J Infect 2009; 58:403–10.
2. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difﬁcile-
associated disease: old therapies and new strategies. Lancet Infect Dis
2005; 5:549–57.
3. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk
factors for recurrent Clostridium difﬁcile infection. J Hosp Infect 2008;
70:298–304.
4. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after
treatment of Clostridium difﬁcile colitis in Quebec, Canada. Clin
Infect Dis 2005; 40:1591–7.
5. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and vali-
dation of a clinical prediction rule for recurrent Clostridium difﬁcile
infection. Gastroenterology 2009; 136:1206–14.
6. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW,
Greenberg RN. Recurrent Clostridium difﬁcile disease: epidemiology
and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20:
43–50.
7. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized
placebo-controlled trial of Saccharomyces boulardii in combination
with standard antibiotics for Clostridium difﬁcile disease. JAMA 1994;
271:1913–8.
8. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of pro-
spective Clostridium difﬁcile-associated disease surveillance and treat-
ment at the Minneapolis VA Medical Center, 1982–1991. Infect
Control Hosp Epidemiol 1994; 15:371–81.
9. Bartlett JG. Narrative review: the new epidemic of Clostridium
difﬁcile-associated enteric disease. Ann Intern Med 2006; 145:758–64.
10. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. Re-
currences of Clostridium difﬁcile diarrhea not caused by the original
infecting organism. J Infect Dis 1989; 159:340–3.
S86 • CID 2012:55 (Suppl 2) • Eyre et al
11. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC.
Epidemiology of recurrences or reinfections of Clostridium difﬁcile-
associated diarrhea. J Clin Microbiol 2000; 38:2386–8.
12. Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symp-
toms in Clostridium difﬁcile infection—relapse or reinfection? J Hosp
Infect 1998; 38:93–100.
13. O’Neill GL, Beaman MH, Riley TV. Relapse versus reinfection with
Clostridium difﬁcile. Epidemiol Infect 1991; 107:627–35.
14. van den Berg RJ, Ameen HA, Furusawa T, Claas EC, van der
Vorm ER, Kuijper EJ. Coexistence of multiple PCR-ribotype strains
of Clostridium difﬁcile in faecal samples limits epidemiological
studies. J Med Microbiol 2005; 54(Pt 2):173–9.
15. Cohen SH, Gerding DN, Johnson S, et al.; Society for Healthcare Epi-
demiology of America; Infectious Diseases Society of America. Clini-
cal practice guidelines for Clostridium difﬁcile infection in adults: 2010
update by the Society for Healthcare Epidemiology of America
(SHEA) and the Infectious Diseases Society of America (IDSA). Infect
Control Hosp Epidemiol 2010; 31:431–55.
16. Louie TJ, Miller MA, Mullane KM, et al.; OPT-80-003 Clinical Study
Group. Fidaxomicin versus vancomycin for Clostridium difﬁcile infec-
tion. N Engl J Med 2011; 364:422–31.
17. Grifﬁths D, Fawley W, Kachrimanidou M, et al. Multilocus sequence
typing of Clostridium difﬁcile. J Clin Microbiol 2010; 48:770–8.
18. Finney JM, Walker AS, Peto TE, Wyllie DH. An efﬁcient record
linkage scheme using graphical analysis for identiﬁer error detection.
BMC Med Inform Decis Mak 2011; 11:7.
19. Royston P, Parmar MK. Flexible parametric proportional-hazards and
proportional-odds models for censored survival data, with application
to prognostic modelling and estimation of treatment effects. Stat Med
2002; 21:2175–97.
20. Burnham KP, Anderson DR. Model selection and multimodel infer-
ence. 2nd ed. New York, NY: Springer, 2002.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribu-
tion of a competing risk. J Am Stat Assoc 1999; 94:496–509.
22. Royston P. Multiple imputation of missing values: update of ice. Stata
J 2005; 5:527–36.
23. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing
blood pressure covariates in survival analysis. Stat Med 1999; 18:681–94.
24. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing
data in epidemiological and clinical research: potential and pitfalls.
BMJ 2009; 338:b2393.
25. Hess KR. Assessing time-by-covariate interactions in proportional hazards
regression models using cubic spline functions. Stat Med 1994; 13:1045–62.
26. Dingle KE, Grifﬁths D, Didelot X, et al. Clinical Clostridium difﬁcile:
clonality and pathogenicity locus diversity. PLoS One 2011; 6:e19993.
27. Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine com-
mercially available Clostridium difﬁcile toxin detection assays, a real-
time PCR assay for C. difﬁcile tcdB, and a glutamate dehydrogenase
detection assay to cytotoxin testing and cytotoxigenic culture
methods. J Clin Microbiol 2009; 47:3211–7.
28. Planche T, Aghaizu A, Holliman R, et al. Diagnosis of Clostridium
difﬁcile infection by toxin detection kits: a systematic review. Lancet
Infect Dis 2008; 8:777–84.
29. Rolfe RD, Helebian S, Finegold SM. Bacterial interference between
Clostridium difﬁcile and normal fecal ﬂora. J Infect Dis 1981; 143:
470–5.
30. Claesson MJ, Cusack S, O’Sullivan O, et al. Composition, variability,
and temporal stability of the intestinal microbiota of the elderly. Proc
Natl Acad Sci U S A 2011; 108(Suppl 1):4586–91.
31. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody
response to toxin A and protection against recurrent Clostridium difﬁ-
cile diarrhoea. Lancet 2001; 357:189–93.
32. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody corre-
lates with protection from recurrent Clostridium difﬁcile infection
(CDI). Vaccine 2010; 28:965–9.
33. Emerson JE, Reynolds CB, Fagan RP, Shaw HA, Goulding D,
Fairweather NF. A novel genetic switch controls phase variable
expression of CwpV, a Clostridium difﬁcile cell wall protein. Mol Mi-
crobiol 2009; 74:541–56.
34. Vonberg R-P, Kuijper EJ, Wilcox MH, et al. Infection control
measures to limit the spread of Clostridium difﬁcile. Clin Microbiol
Infect 2008; 14(Suppl 5):2–20.
35. Eyre DW, Walker AS, Grifﬁths D, et al. Clostridiium difﬁcile mixed
infection and reinfection. J Clin Microbiol 2012; 50:142–4.
36. Eastwood K, Wilcox MH. Do enzyme immunoassays (EIAs) for Clos-
tridium difﬁcile toxins yield higher optical densities for faecal samples
that are ribotype 027 culture-positive? [abstract D-126]. Presented at:
50th Interscience Conference on Antimicrobial Agents and Che-
motherapy, 12–15 September 2010, Boston, Massachusetts.
37. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difﬁcile and
inﬂammatory bowel disease. Inﬂamm Bowel Dis 2008; 14:
1432–42.
38. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of Clostridium difﬁcile
infection in hospitalized pediatric patients with inﬂammatory bowel
disease. Inﬂamm Bowel Dis 2011; 17:50–5.
39. Selinger CP, Greer S, Sutton CJ. Is gastrointestinal endoscopy a risk
factor for Clostridium difﬁcile associated diarrhea? Am J Infect
Control 2010; 38:581–2.
40. Rodrigues MA, Brady RR, Rodrigues J, Graham C, Gibb AP.
Clostridium difﬁcile infection in general surgery patients; identiﬁcation
of high-risk populations. Int J Surg 2010; 8:368–72.
41. Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavour-
able outcomes in Clostridium difﬁcile infection: a systematic review.
PLoS One 2012; 7:e30258.
42. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology
of Clostridium difﬁcile infections. Clin Microbiol Rev 2010; 23:
529–49.
43. Burns DA, Heap JT, Minton NP. The diverse sporulation character-
istics of Clostridium difﬁcile clinical isolates are not associated with
type. Anaerobe 2010; 16:618–22.
44. Sirard S, Valiquette L, Fortier LC. Lack of association between clinical
outcome of Clostridium difﬁcile infections, strain type, and virulence-
associated phenotypes. J Clin Microbiol 2011; 49:4040–6.
45. Kim JW, Lee KL, Jeong JB, et al. Proton pump inhibitors as a risk
factor for recurrence of Clostridium-difﬁcile-associated diarrhea.
World J Gastroenterol 2010; 16:3573–7.
Predictors of CDI Recurrence • CID 2012:55 (Suppl 2) • S87
